双氟泼尼酯治疗葡萄膜炎性黄斑囊样水肿
回顾性介入病例系列纳入58例(72眼)葡萄膜炎性黄斑囊样水肿患者,局部使用双氟泼尼酯0.05%滴眼液。30天时单用双氟泼尼酯眼黄斑中心亚区厚度平均下降17%,联用全身免疫抑制治疗眼下降6%,组间差异12%(P=.02)。作者认为双氟泼尼酯与黄斑囊样水肿改善相关,可作为合理的一线治疗,但应密切监测眼压。
要点
- 单用双氟泼尼酯眼30天时76%黄斑囊样水肿改善、48%消退。
- 联用全身免疫抑制治疗眼37%改善、17%消退。
- 30天内8眼(11%)眼压>24 mmHg,应密切监测眼压。
核心结论
- 双氟泼尼酯与葡萄膜炎性黄斑囊样水肿的改善相关,可能是合理的一线治疗。
- 使用双氟泼尼酯时应密切监测眼压。
研究设计与样本
- 回顾性、介入性病例系列,在三级葡萄膜炎中心进行病历回顾。
- 纳入2012年6月至2016年5月期间接受双氟泼尼酯0.05%滴眼液治疗的58例患者(72眼)葡萄膜炎性黄斑囊样水肿。
主要发现
- 30天时,单用双氟泼尼酯眼(n=43)黄斑中心亚区厚度平均下降17%(95%CI:-33%,-7%)。
- 30天时,联用全身免疫抑制治疗眼(n=29)黄斑中心亚区厚度平均下降6%(95%CI:-17%,-2%);组间差异12%(95%CI:2%,21%,P=.02)。
- 单用双氟泼尼酯眼中76%黄斑囊样水肿改善、48%消退;联用全身免疫抑制治疗眼中37%改善、17%消退。
- 30天内8眼(11%)眼压>24 mmHg。
- 90天时,全部眼中69%黄斑囊样水肿改善、43%消退;仅9例患者开始或增加全身免疫抑制药物,2例患者接受眼周皮质类固醇注射。
关键数值与推荐
- 黄斑囊样水肿改善定义为黄斑中心亚区厚度较基线降低≥20%或消退。
- 黄斑囊样水肿消退定义为黄斑中心亚区厚度≤320 μm且无囊样改变。
- 主要结局于开始治疗后30天评估,结局评估至90天。
临床怎么用
- 作者认为双氟泼尼酯可能是葡萄膜炎性黄斑囊样水肿合理的一线治疗。
- 作者建议密切监测眼压。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To describe clinical outcomes associated with the use of topical difluprednate in treating uveitic cystoid macular edema. DESIGN: Retrospective, interventional case series. METHODS: Setting: Medical record review in a tertiary care uveitis center. PATIENT POPULATION: Fifty-eight patients (72 eyes) with uveitic cystoid macular edema (CME) treated with difluprednate 0.05% ophthalmic solution between June 2012 and May 2016. MAIN OUTCOME MEASURES: Macular central subfield thickness (CST) determined by optical coherence tomography, improvement of CME (≥20% reduction in CST or resolution), and resolution of CME (CST ≤ 320 μm with no cysts) at 30 days after starting treatment. Outcomes were assessed up to 90 days. RESULTS: CST on average decreased by 17% (95% CI: -33%, -7%) for eyes using only difluprednate (n = 43) and by 6% (95% CI: -17%, -2%) for eyes in patients using concomitant systemic immunosuppressive therapy (n = 29) at 30 days, a 12% difference between groups (95% CI: 2%, 21%, P = .02). Of eyes on difluprednate alone, 76% had improvement and 48% had resolution of CME. In patients using systemic therapy, 37% of eyes had improvement and 17% had resolution. Eight eyes (11%) had an intraocular pressure (IOP) > 24 mm Hg within the first 30 days. By 90 days, CME had improved in 69% of all eyes and resolved in 43% of eyes, with only 9 patients starting or increasing systemic immunosuppressive medications and 2 patients receiving periocular corticosteroid injections. CONCLUSIONS: Difluprednate was associated with an improvement in uveitic CME and could be a reasonable first-line therapy. IOP should be closely monitored.
引用
- Schallhorn JM, Niemeyer KM, Browne EN, et al. Difluprednate for the Treatment of Uveitic Cystoid Macular Edema. Am J Ophthalmol. 2018. PMID: 29580977. doi:10.1016/j.ajo.2018.03.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。